In a phase I study, Fearon and his colleagues discovered that inhibiting the chemokine receptor type 4 (CXCR4) for one week can activate immune reactions in cancer cells and tumor biopsies. The study also led to the discovery that CXCR4 protects all of the cancer cells and CXCL-12 coats several adenocarcinomas. Read more . . .